The Angelman Syndrome Foundation (ASF) has announced that Dr. Elizabeth Jalazo, a pediatrician at the University of North Carolina in Chapel Hill, will take on the new position of Director of Clinical Integration for the ASF. In her role as […]
Read moreImportant work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is critically important to design […]
Read more
Your ASF donations hard at work at UNC and Erasmus Medical Center in the Netherlands. This pivotal study demonstrated that UBE3A is most critical in the developing brain and plays a less vital role later on in life. This is […]
Read moreAnxiety in Angelman Syndrome Important work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is […]
Read more
See the following announcement from May 16, 2019. Also, see a Q&A on this collaboration for more details. Dear Angelman Syndrome Community, We, Roche, Biogen and Ionis, are amongst several companies working towards finding potential treatments for Angelman Syndrome (AS). […]
Read more
ASF partners with AS father and advocate to celebrate global strides in Angelman syndrome research, patient care AURORA, Ill. (Feb. 15, 2019) – Today, in celebration of International Angelman Day on Feb. 15, the Angelman Syndrome Foundation (ASF) partnered with Angelman […]
Read more
Comprehensive Clinics Provide Unique Support for Individuals with Angelman Syndrome in Canada and Israel AURORA, Ill. (December 6, 2018) – The Angelman Syndrome Foundation (ASF) expands its Angelman Syndrome Clinic Network through collaboration with international partners: The Children’s Hospital of Eastern Ontario in Ottawa, Canada, and the Edmond and […]
Read more
On December 6, 2018, Ovid Therapeutics announced plans to move ahead with a single, pivotal Phase 3 trial of once-daily dosing of OV101 in pediatric patients with Angelman syndrome. This is based on its End-of-Phase 2 Meeting with the U.S. […]
Read more
